Trials / Completed
CompletedNCT00874887
A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | moxifloxacin 0.5% HCI ophthalmic solution | 1 drop in study eye three times a day for 14 days |
| DRUG | gatifloxacin ophthalmic solution 0.3% | 1 drop in study eye four times a day for 14 days |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2009-09-01
- Completion
- 2009-10-01
- First posted
- 2009-04-03
- Last updated
- 2011-12-19
- Results posted
- 2011-12-19
Locations
2 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00874887. Inclusion in this directory is not an endorsement.